万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://academic.oup.com/carcin
3、投稿网址：http://mc.manuscriptcentral.com/carcin
4、官网邮箱：carcinogenesis.editorialoffice@oup.com
5、期刊刊期：月刊，一年出版十二期。
2021年5月21日星期五
投稿须知【官网信息】
Instructions to authors
All material to be considered for publication in Carcinogenesis must be submitted in electronic form via the Journal's online submission system. Once you have prepared your manuscript according to the Instructions below, please visit the online submission system here.
For instructions on how to submit your manuscript online please click here.
Scope and policy of Carcinogenesis
Carcinogenesis: Integrative Cancer Research is a multi-disciplinary journal that brings together all the varied aspects of research that will ultimately lead to the prevention of cancer in humans. The journal publishes papers that warrant prompt publication in the areas of Biology, Genetics and Epigenetics (including the processes of promotion, progression, signal transduction, apoptosis, genomic instability, growth factors, cell and molecular biology, mutation, DNA repair, genetics, etc.), Cancer Biomarkers andMolecular Epidemiology (including genetic predisposition to cancer, and epidemiology), Inflammation, Microenvironment and Prevention (including molecular dosimetry, chemoprevention, nutrition and cancer, etc.), and Carcinogenesis (including oncogenes and tumor suppressor genes in carcinogenesis, therapy resistance of solid tumors, cancer mouse models, apoptosis and senescence, novel therapeutic targets and cancer drugs). The Editors may, from time to time, invite reviews. Authors wishing to propose or submit a review article should contact the Editorial Office at carcinogenesis.editorialoffice@oup.com before submission.
Commentaries: Carcinogenesis welcomes Commentaries which should include long comments or personal observations on current research or trends in cancer research and epidemiology that is likely to be of interest to Carcinogenesis readers. Maximum 1,500 words, 250 word abstract, 15 references and 1 table or figure.
Cell line authentication
Carcinogenesis requires authors to report on the authentication of all cell lines reported in their research. A statement addressing the following points must be included in the Materials and Methods section of the manuscript:
From where and when the cells were obtained.
Whether the cell lines have been tested and authenticated.
The method by which the cells were tested.
How and when the cells were last tested.
Reauthentication is not required if cells were obtained directly from a cell bank that performs cell line characterizations, subject to the cells being passaged in the user's laboratory for fewer than 6 months after receipt or resuscitation. In such cases, authors should include the method of characterization used by the cell bank.
Further information on cell line authentication is available here: UKCCCR Guidelines for the Use of Cell Lines in Cancer Research http://www.nature.com/bjc/journal/v82/n9/abs/6691169a.html.
Ethics
Carcinogenesis is a member of the Committee on Publication Ethics (COPE), and strives to adhere to its code of conduct and guidelines.
Authors are encouraged to consult http://publicationethics.org/resources/guidelines for more information.
In reports of investigations in humans or animals, authors must explicitly indicate (in the appropriate section of the Methods) their adherence to ethical standards and note the approval of an ethics committee when this is relevant
Submission of manuscripts
Carcinogenesis accepts submissions online http://mc.manuscriptcentral.com/carcin
Manuscripts should be in their final form when they are submitted so that proofs will require only correction of typographical errors. Manuscripts must be submitted according to the manuscript template, available online here. A mini-style checklist is also available online here.
For any queries please contact the editorial office:
Email:carcinogenesis.editorialoffice@oup.com.
Final accepted papers must be uploaded in a workable format NOT pdf files.
Submission of a paper implies that it reports unpublished work and that it is not under consideration for publication elsewhere. If previously published tables, illustrations or more than 200 words of text are to be included, then the copyright holder's written permission must be obtained. Copies of any such permission letters should be sent to the relevant Editor. The Carcinogenesis Editorial team reserve the right to use CrossCheck. CrossCheck is an initiative started by CrossRef to help its members actively engage in efforts to prevent scholarly and professional plagiarism.
Authors should identify the section in which they wish their paper to appear, i.e. Biology, Genetics and Epigenetics; Cancer Biomarkers and Molecular Epidemiology; Inflammation, Microenvironment and Prevention; Carcinogenesis; or Review, using the designated box within the Manuscript Data Sheet online. The online submission process also requires the author to provide the names and addresses of 3 or 4 potential referees.
Authorship: All persons designated as authors should qualify for authorship. The order of authorship should be a joint decision of the co-authors. Each author should have participated sufficiently in the work to take public responsibility for the content. Authorship credit should be based on substantial contribution to conception and design, execution, or analysis and interpretation of data. All authors should be involved in drafting the article or revising it critically for important intellectual content, and must have read and approved the final version of the manuscript. Assurance that all authors of the paper have fulfilled these criteria for authorship should be given in the covering letter.
Advanced access
Advance Access is the journal's system for the early online publication of articles ahead of the printed issue. Manuscripts are published online as soon as possible after they have been accepted, with updates on a daily basis. In order to achieve this rapid publication time, the accepted manuscript is published online before copyediting and formatting has been carried out, this version is indicated by the text 'Accepted Manuscript'. A second copyedited, typeset, corrected version may also be published online ahead of print; this version is indicated by the text 'Corrected Proof'. Appearance in Advance Access constitutes official publication, and the Advance Access version can be cited using the author name(s), Carcinogenesis, the year of publication and the unique DOI (digital object identifier), for example: Kattoa, J. et al. (2011) Epigenetic Regulation of Cellular Adhesion in Cancer. Carcinogenesis, 10.1093/carcin/bgr120.
Proofs
After acceptance of the article authors will sent links to their proofs by the typesetter for checking. To avoid delays in publication, proofs should be checked immediately for typographical errors and returned within 3 days.
Extensive changes of an essential nature may be made only by insertion of a Note Added in Proof. A charge will be made to authors who insist on amendment to the text at the proof stage. It is the author's responsibility to check that all the text and data as contained in the page proofs are suitable for publication.
Preparation of manuscripts
Manuscripts should be in their final form when they are submitted so that proofs will require only correction of typographical errors. Manuscripts must be submitted according to the manuscript template, available online here. A mini-style checklist is also available online here.
Sections of the manuscript Regular full-length papers should be subdivided into the following sequence of sections: Title page, Abstract, Introduction, Materials and methods, Results, Discussion, Acknowledgements, References, Tables, Legends to Figures. In the journal the Materials and methods, Acknowledgements and References will be printed in smaller type to accommodate more text.
Authors should follow the below guidelines for manuscript length:
5000 words (excluding references and figure legends)
6 or fewer tables and/or figures (6 in total)
250 word limit for the abstract
50 references
In addition to the abstract, manuscripts should also include a 40-word summary of the article's main point. This may be used to highlight the article in the contents list online and in e-mail alerts. Such a summary is not compulsory, but is likely to encourage readers browsing the table of contents to read your article.
Supplementary Material Only directly relevant material should be included in the full text of manuscripts. Supporting materials which are not essential in the full text, but would nevertheless benefit the reader, can be published as online-only supplementary data. Supplementary data should be submitted for review, in a separate file from the manuscript. Authors should ensure that supplementary data is referred to in the main manuscript at an appropriate point in the text.
Language editing
Particularly if English is not your first language, before submitting your manuscript you may wish to have it edited for language. This is not a mandatory step, but may help to ensure that the academic content of your paper is fully understood by journal editors and reviewers. Language editing does not guarantee that your manuscript will be accepted for publication. If you would like information about language editing click here. Authors are liable for all costs associated with such services.
General format
As referees may choose to print out your paper for reviewing purposes, all sections of the manuscript must be double-spaced with margins of 25mm (one inch) left at the sides, top and bottom of each page. Number each page top right (Title Page is 1). Please avoid footnotes, use instead, and as sparingly as possible, parenthesis within brackets.
Abstract
The second page of every manuscript must contain only the Abstract, which should be a single paragraph not exceeding 250 words. Published papers will only have the first 250 words of their abstracts incorporated into Medline, text in excess of this limit will be lost. The Abstract should be comprehensible to readers before they have read the paper, and abbreviations and reference citations should be avoided.
NEW
Authors are encouraged to submit a graphical abstract as part of the article, in addition to the text abstract. The graphical abstract should clearly summarize the focus and findings of the article, and will be published as part of the article online and in PDF. The graphical abstract should be submitted for peer review as a separate file, selecting the appropriate file-type designation in the journal’s online submission system. The file should be clearly named, e.g.graphical_abstract.tiff. See this page for guidance on appropriate file format and resolution for graphics.
Acknowlegements
These should be included at the end of the text and not in footnotes. Personal acknowledgements should precede those of institutions or agencies.
References
Authors are responsible for the accuracy of the References. Published articles and those in press (state the journal which has accepted them) may be included. Arrange references in numerical order with the numbers in the text in brackets and on the line (not as superscripts). In the reference list please note that for more than one author the first author name should be mentioned and the initials follow the name; then et al. The date should precede the title; the title should be given in full; the name of the journal should be abbreviated according to the World List of Scientific Periodicals and underlined to indicate italics. References should therefore be listed as follows:
Wilting, S. M. et al. (2010) Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol. Cancer, 9, 167.
Hatch, F. Tet al (1984) Identification of mutagens from the cooking of food. In de Serres, F. J. (ed.) Chemical Mutagens: Principles and Methods for their Detection. Plenum Press, New York, vol. 9, pp. 111-164.
Rothman K. J. et al. (1998) Modern Epidemiology. Lippincott Williams and Wilkins, Philadelphia.
Personal communications (J. Smith, personal communication) should be authorized by those involved, in writing, and unpublished data should be cited as (unpublished data). Both should be used as sparingly as possible and only when the unpublished data referred to is peripheral rather than central to the discussion. References to manuscripts in preparation, or submitted but not yet accepted, should be cited in the text as (B. Smith and N. Jones, in preparation) and should NOT be included in the list of references.
Tables
Tables should be numbered consecutively with Roman numerals, they should be self-explanatory and include a brief descriptive title. Footnotes to tables indicated by lower case letters are acceptable, but they should not include extensive experimental detail. Please supply as rich text format or a word document not as a powerpoint attachment.
Requirements for images
The Journal recommends, but does not require, authors to make available full blots as supplementary data - to avoid the risk of claims from readers in the future with respect to image manipulation. As with all data being reported, editors may request to review original data/images either during the review process or post-publication. Authors are advised of their responsibility to archive original data for a suitable time period after study closure.
Image manipulation beyond minimal processing (for instance, to add arrows to a micrograph) is strictly forbidden. All digitized images submitted with the final version of the manuscript must be of high quality and have resolutions of at least 300 d.p.i for colour, 600 d.p.i. for greyscale and for .eps format 1200 d.p.i. for line art.
All images must accurately represent the original data in line with the latest standards now expected by the research community.
Please list in the methods all tools and software used to acquire images, including image-gathering settings and any required processing manipulations.
Single images created from separately acquired (eg, different times or from different locations) are not permitted unless it is clearly stated in the legend that the combined image is, for example, time-averaged data or a time-lapse sequence. If comparative images are required in one figure then separate images must be demarcated in the whole figure and described in the legend.
Changing contrast or brightness may be acceptable when it is applied evenly over the whole image including over the controls. Reducing or increasing contrast to hide data is forbidden. Processing to emphasize a region in an image to the detriment of other regions is inappropriate, particularly where an attempt is made to reinforce significance of experimental data relative to the control.
Use of cloning and healing tools, such as those available in Photoshop, or any feature that deliberately obscures manipulations, is considered inappropriate. Where such tools are used by necessity, for example to remove identifying data about patients from an image, then this should be explicitly mentioned in the figure legend.
Electrophoretic gels and blots
Carcinogenesis allows cropped gels and blots, but cropping must be indicated in the image and mentioned in the figure legend. If a manuscript is accepted, the Journal recommends, but it is not compulsory, that full-length gels and/or blots are made available as supplementary data.
All gels must include positive and negative controls, as well as molecular size markers; where these are not visible in the cropped figure then such controls must show clearly in the expanded data supplementary figure.
Please provide a citation for characterized antibodies. Where a citation is not yet available, then a detailed characterization demonstrating the specificity of the antibody and the range of reactivity of the reagent in the assay, should be supplied as supplementary information. Carcinogenesis recommends submission of data and linking with an antibody profile database (e.g., Antibodypedia, 1DegreeBio).
While Carcinogenesis discourages quantitative comparisons between samples on different gels/blots, if this is part of the experiment reported, then the legend must state that the samples derive from the same experiment and that gels/blots were processed in parallel. Sliced images that compare lanes that were non-adjacent in the original gel must have a dark line delineating the boundary between the gels. Loading controls (eg, GAPDH, actin) must be run on the same blot. Sample processing controls run on different gels must be identified as such, and distinctly from loading controls.
Cropped gels/blots in the paper must retain important bands, and Carcinogenesis recommends at least six band widths above and below the band under investigation.
Overexposure may mask additional bands and high-contrast gels and blots are therefore discouraged. Gray backgrounds are expected as the norm. If high contrast is unavoidable then multiple exposures should be presented in supplementary information.
For quantitative comparisons, appropriate reagents, controls and imaging methods with linear signal ranges should be used.
Illustrations
All illustrations (line drawings and photographs) should be referred to in the text as Figure 1 etc., abbreviated to 'Fig. 1.' only in the figure legend. Wherever possible, figures will be sized to fit the width of a single column of text, i.e., 88mm wide. The maximum width of a double column figure is 183mm, the maximum depth is 240mm. Figures with low density data will all be single column width. Please consider the overall page dimensions and layout, and the final reduction necessary for printing. Figures must be at a minimum resolution of 600 d.p.i. for line drawings (black and white) and 300 d.p.i. for colour or greyscare. Any lettering should be ~2mm in height in the printed figure (after reduction) and should be in proportion to the overall dimensions of the drawing. Labels should not be disproportionally large, and should show up clearly against the background.
Photographs
Wherever possible, these must be submitted in the desired final size so that reduction can be avoided. Ideally, photographs should fit either a single column (88mm) or a double column (183mm). Photographs should be of sufficiently high quality with respect to detail, contrast and fineness of grain to withstand the inevitable loss of contrast and detail inherent in the printing process. Please indicate the magnification by a rule on the photographs.
Colour figures
There is a special charge for the inclusion of colour figures. The cost is £350 / $600 per figure. (For cost purposes, the definition of a single figure is artwork that can be processed as a unit and printed on a single page without intervening type. Authors should note the potential cost savings inherent in this definition; for example, two consecutive half-page colour figures mounted as a composite and printed on one page, with both legends below or on the facing page, would be treated as one figure.) If there is a choice of colours on a schematic, please choose clearly distinct colours (e.g. not two shades of blue) and avoid black backgrounds if possible.
For useful information on preparing your figures for publication, go to http://cpc.cadmus.com/da.
Line drawings
Please provide clear, sharp prints, suitable for reproduction as submitted. No additional artwork, redrawing or typesetting will be done. Therefore, all labelling should preferably be made with a lettering set. Ensure that the size of lettering is in proportion with the overall dimensions of the drawing. Ideally, line drawings should be submitted in the desired final size to avoid reduction (maximum dimensions 248 x 185 mm including legends) and should fit either a single (88 mm) or a double column width (185 mm). If submitting line drawings which require reduction, please check that the lettering will be clearly legible after reduction to the size at which it will be printed. After reduction, letters should not be smaller than 1.5 mm in height.
Figure legends
Figure legends should follow the reference list. Define all symbols and abbreviations used in the figure. Common abbreviations and others in the preceding text should not be redefined in the legend.
Conventions
In general, the journal follows the conventions of the CBE Style Manual (Council of Biology Editors, Bethesda, MD, 1983, 5th edn).
Follow Chemical Abstracts and its indexes for chemical names. For guidance follow the recommendations issued by the IUPAC-IUB Commission on Bio-chemical Nomenclature, as given in Biochemical Nomenclature and Related Documents, published by the Biochemical Society, UK. For enzymes, use the recommended name assigned by the IUPAC-IUB Commission on Bio-chemical Nomenclature, 1978, as given in Enzyme Nomenclature, published by Academic Press, New York, 1980. Where possible, use recommended SI (Systeme International) units.
Genotypes should be italicized (underline in typed copy); phenotypes should not be italicized. For bacterial genetics nomenclature follow Demerec et al. (1966) Genetics, 54, 61-76.
Abbreviations
Restrict the use of abbreviations to SI symbols and those recommended by the IUPAC. Abbreviations should be defined in brackets after their first mention in the text. Standard units of measurements and chemical symbols of elements may be used without definition.
Availability of Data and Materials
Where ethically feasible, Carcinogenesis strongly encourages authors to make all data and software code on which the conclusions of the paper rely available to readers. Authors are required to include a Data Availability Statement in their article.
We suggest that data be presented in the main manuscript or additional supporting files, or deposited in a public repository whenever possible. For information on general repositories for all data types, and a list of recommended repositories by subject area, please see Choosing where to archive your data.
Data Availability Statement
The inclusion of a Data Availability Statement is a requirement for articles published in Carcinogenesis. Data Availability Statements provide a standardised format for readers to understand the availability of data underlying the research results described in the article. The statement may refer to original data generated in the course of the study or to third-party data analysed in the article. The statement should describe and provide means of access, where possible, by linking to the data or providing the required unique identifier.
The Data Availability Statement should be included in the endmatter of your article under the heading ‘Data availability’.
More information and examples of Data Availability Statements.
Data Citation
Carcinogenesis supports the Force 11 Data Citation Principles and requires that all publicly available datasets be fully referenced in the reference list with an accession number or unique identifier such as a digital object identifier (DOI). Data citations should include the minimum information recommended by DataCite:
[dataset]* Authors, Year, Title, Publisher (repository or archive name), Identifier
*The inclusion of the [dataset] tag at the beginning of the citation helps us to correctly identify and tag the citation. This tag will be removed from the citation published in the reference list.
Preprint policy
Authors retain the right to make an Author’s Original Version (preprint) available through various channels, and this does not prevent submission to the journal. For further information see our Online Licensing, Copyright and Permissions policies. If accepted, the authors are required to update the status of any preprint, including your published paper’s DOI, as described on our Author Self-Archiving policy page.
ORCID
Carcinogenesis requires submitting authors to provide an ORCID iD at submission to the journal. More information on ORCID and the benefits of using an ORCID iD is available. If you do not already have an ORCID iD, you can register for free via the ORCID website.
Licence to publish and conflict of interest
Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright licence to publish form.
Please note that by submitting an article for publication you confirm that you are the corresponding/submitting author and that Oxford University Press ("OUP") may retain your email address for the purpose of communicating with you about the article. You agree to notify OUP immediately if your details change. If your article is accepted for publication OUP will contact you using the email address you have used in the registration process. Please note that OUP does not retain copies of rejected articles.
It is a condition of publication in the Journal that authors grant an exclusive licence to Oxford University Press. This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and will also allow the article to be as widely disseminated as possible. In giving this exclusive licence, authors may use their own material in other publications provided that the Journal is notified and acknowledged as the original place of publication, and that Oxford University Press is notified in writing and in advance.
Creative Commons Information
At the point of submission, Carcinogenesis Journal’s policy requires that each author reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated - including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition. When considering whether you should declare a conflicting interest or connection please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it?
As an integral part of the online submission process, Corresponding authors are required to confirm whether they or their co-authors have any conflicts of interest to declare, and to provide details of these. If the Corresponding author is unable to confirm this information on behalf of all co-authors, the authors in question will then be required to submit a completed Conflict of Interest form to the Editorial Office. It is the Corresponding author’s responsibility to ensure that all authors adhere to this policy.
If the manuscript is published, Conflict of Interest information will be communicated in a statement in the published paper.
Open access option for authors
Carcinogenesis offers the option of publishing under either a standard licence or an open access licence. Please note that some funders require open access publication as a condition of funding. If you are unsure whether you are required to publish open access, please do clarify any such requirements with your funder or institution.
Should you wish to publish your article open access, you should select your choice of open access licence in our online system after your article has been accepted for publication. You will need to pay an open access charge to publish under an open access licence.
Details of the open access licences and open access charges.
OUP has a growing number of Read and Publish agreements with institutions and consortia which provide funding for open access publishing. This means authors from participating institutions can publish open access, and the institution may pay the charge. Find out if your institution is participating.
Third-party content in open access papers
If you will be publishing your paper under an Open Access licence but it contains material for which you do not have Open Access re-use permissions, please state this clearly by supplying the following credit line alongside the material:
Title of content ; author, original publication, year of original publication, by permission of [rights holder]. This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission to reuse, please contact the rights holder.
Author self-archiving/public access policy
For information about this journal's policy, please visit our Author Self-Archiving policy page.
Crossref funding data registry & NIH funding
In order to meet your funding requirements authors are required to name their funding sources, or state if there are none, during the submission process. For further information on this process or to find out more about the CHORUS initiative please click here.
Details of all funding sources for the work in question should be given in a separate section entitled 'Funding'. This should appear before the 'Acknowledgements' section.
Oxford Journals will deposit all NIH-funded articles in PubMed Central. See https://academic.oup.com/journals/pages/authors for details. Authors must ensure that manuscripts are clearly indicated as NIH-funded using the guidelines below.
The following rules should be followed:
The sentence should begin: ‘This work was supported by …’
The full official funding agency name should be given, i.e. ‘National Institutes of Health’, not ‘NIH’ (full RIN-approved list of UK funding agencies) Grant numbers should be given in brackets as follows: ‘[grant number xxxx]’
Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers xxxx, yyyy]’
Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency)
Where individuals need to be specified for certain sources of funding the following text should be added after the relevant agency or grant number 'to [author initials]'.
An example is given here: ‘This work was supported by the National Institutes of Health [AA123456 to C.S., BB765432 to M.H.]; and the Alcohol & Education Research Council [hfygr667789].’
